Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis

Cancer Genetics and Cytogenetics
Bhuvaneswari RamkumarMaria R Baer

Abstract

Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS). We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL). These constitute, to our knowledge, the eighth and ninth reports of APL in patients treated with mitoxantrone for MS. Topoisomerase 2 inhibitors are associated with therapy-related acute myeloid leukemia (t-AML) with 11q23 abnormalities, but therapy-related APL (t-APL) is less common, and documentation of nine cases of t-APL after mitoxantrone therapy for MS suggests a specific association.

References

Aug 1, 1991·Cancer Genetics and Cytogenetics·J Pedersen-Bjergaard, P Philip
Jun 1, 1994·British Journal of Haematology·P Fenaux, L Detourmignies
Feb 14, 1998·Cancer Letters·C E FrantzD A Eastmond
Sep 28, 1998·Biochimica Et Biophysica Acta·C A Felix
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M BeaumontP Fenaux
Nov 26, 2003·Neurology·D S GoodinUNKNOWN Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Apr 15, 2005·The New England Journal of Medicine·Anita R MistryDavid Grimwade
May 19, 2005·American Journal of Clinical Pathology·C Cameron YinL Jeffrey Medeiros
Aug 17, 2005·Arquivos de neuro-psiquiatria·Walter Oleschko ArrudaRicardo Ramina

❮ Previous
Next ❯

Citations

Mar 10, 2012·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Nada SuvajdžićDragica Tomin
Mar 11, 2009·The Medical Clinics of North America·Ardith M CourtneyElliot Frohman
Dec 3, 2014·Blood Reviews·L ZhangC Metayer
Feb 18, 2011·Multiple Sclerosis : Clinical and Laboratory Research·E Le PageUNKNOWN French Mitoxantrone Safety Group
Oct 15, 2009·Multiple Sclerosis : Clinical and Laboratory Research·Ana M PascualBonaventura Casanova
Apr 1, 2019·Best Practice & Research. Clinical Haematology·Prajwal C Boddu, Amer M Zeidan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.